134 related articles for article (PubMed ID: 27130921)
1. Oncolytic Virus Approved To Treat Melanoma.
Schmidt C
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 27130921
[No Abstract] [Full Text] [Related]
2. First Oncolytic Viral Therapy for Melanoma.
Poh A
Cancer Discov; 2016 Jan; 6(1):6. PubMed ID: 26552414
[TBL] [Abstract][Full Text] [Related]
3. [The Advances of Oncolytic Herpes Simplex Virus in Cancer Therapy].
Hao M; Huang C; Xia N
Bing Du Xue Bao; 2016 Jul; 32(4):516-22. PubMed ID: 29996042
[TBL] [Abstract][Full Text] [Related]
4. Herpes simplex virus oncolytic vaccine therapy in melanoma.
Sivendran S; Pan M; Kaufman HL; Saenger Y
Expert Opin Biol Ther; 2010 Jul; 10(7):1145-53. PubMed ID: 20515292
[TBL] [Abstract][Full Text] [Related]
5. Talimogene Laherparepvec for the Treatment of Advanced Melanoma.
Ott PA; Hodi FS
Clin Cancer Res; 2016 Jul; 22(13):3127-31. PubMed ID: 27146699
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives.
Taguchi S; Fukuhara H; Todo T
Jpn J Clin Oncol; 2019 Mar; 49(3):201-209. PubMed ID: 30462296
[TBL] [Abstract][Full Text] [Related]
7. Awaiting a moment of truth for oncolytic viruses.
Schmidt C
J Natl Cancer Inst; 2013 May; 105(10):675-6. PubMed ID: 23650626
[No Abstract] [Full Text] [Related]
8. Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?
Rothermel LD; Zager JS
Expert Opin Biol Ther; 2018 Dec; 18(12):1199-1207. PubMed ID: 30392405
[TBL] [Abstract][Full Text] [Related]
9. Measles virus in cancer therapy.
Mühlebach MD
Curr Opin Virol; 2020 Apr; 41():85-97. PubMed ID: 32861945
[TBL] [Abstract][Full Text] [Related]
10. Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma.
Corrigan PA; Beaulieu C; Patel RB; Lowe DK
Ann Pharmacother; 2017 Aug; 51(8):675-681. PubMed ID: 28351167
[TBL] [Abstract][Full Text] [Related]
11. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
Kohlhapp FJ; Zloza A; Kaufman HL
Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
[TBL] [Abstract][Full Text] [Related]
12. Talimogene laherparepvec (Imlygic) for unresectable melanoma.
Med Lett Drugs Ther; 2016 Jan; 58(1486):8-9. PubMed ID: 26761342
[No Abstract] [Full Text] [Related]
13. Therapeutic oncolytic viruses: clinical advances and future directions.
Warner SG; O'Leary MP; Fong Y
Curr Opin Oncol; 2017 Sep; 29(5):359-365. PubMed ID: 28678032
[TBL] [Abstract][Full Text] [Related]
14. On the treatment of melanoma: A mathematical model of oncolytic virotherapy.
Ramaj T; Zou X
Math Biosci; 2023 Nov; 365():109073. PubMed ID: 37660975
[TBL] [Abstract][Full Text] [Related]
15. Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18.
Au GG; Beagley LG; Haley ES; Barry RD; Shafren DR
Virol J; 2011 Jan; 8():22. PubMed ID: 21241513
[TBL] [Abstract][Full Text] [Related]
16. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
Harrington KJ; Puzanov I; Hecht JR; Hodi FS; Szabo Z; Murugappan S; Kaufman HL
Expert Rev Anticancer Ther; 2015; 15(12):1389-403. PubMed ID: 26558498
[TBL] [Abstract][Full Text] [Related]
17. Interview with Robert Coffin, inventor of T-VEC: the first oncolytic immunotherapy approved for the treatment of cancer.
Coffin R
Immunotherapy; 2016 Feb; 8(2):103-6. PubMed ID: 26799112
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer.
Hamid O; Hoffner B; Gasal E; Hong J; Carvajal RD
Cancer Immunol Immunother; 2017 Oct; 66(10):1249-1264. PubMed ID: 28712033
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint Blockade Plus Oncolytic Virus: A Hot Therapeutic Cancer Strategy.
Robert C
Trends Mol Med; 2017 Nov; 23(11):983-985. PubMed ID: 29137714
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic viruses move forward in clinical trials.
Rowan K
J Natl Cancer Inst; 2010 May; 102(9):590-5. PubMed ID: 20421567
[No Abstract] [Full Text] [Related]
[Next] [New Search]
